Drug firms may be spending as much as €91m a year on lobbying in EuropeBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e2465 (Published 30 March 2012) Cite this as: BMJ 2012;344:e2465
- Michael Day
The drug industry’s lobbying power in Europe dwarfs that of opposing campaign groups and is largely hidden thanks to lax rules that allow drug companies to conceal how much they spend on attempts to influence European Union policy, a new report claims.
The report, produced by the charities Corporate Europe Observatory and Health Action International Europe, says that the industry is known to spend more than €40m (£33m; $53m) a year in attempts to influence decision making in the EU. It says that nearly half of this sum is spent by drug manufacturers on their own in-house lobbyists.
By contrast, campaign groups active on …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.